

Cite this: *Food Funct.*, 2024, **15**, 12007

## Enzymatic treatment to decrease the allergenicity of Pru p 3 from peach†

Ana P. Tobajas, <sup>a,c</sup> Ana Agulló-García, <sup>b,c</sup> José L. Cubero, <sup>b,c</sup> Carlos Colás, <sup>b,c,d</sup> Alba Civera, <sup>a,c</sup> Clara Esteban, <sup>a</sup> Lourdes Sánchez <sup>a</sup> and María D. Pérez <sup>\*a,c</sup>

Pru p 3, a member of the lipid transfer protein family, is considered a major allergen from peach as it often induces serious allergic reactions in peach-allergic individuals. The high resistance of Pru p 3 to processing treatments and to digestion or enzymatic hydrolysis is probably the cause of the severity of this fruit allergy. The aim of this study was to determine the effect of treatment with a large number of proteases from different origins (vegetal, animal and microbial) on the degradation and allergenicity of Pru p 3. To perform this study, Pru p 3 was previously isolated using cation exchange chromatography and ultrafiltration, and the purified protein was incubated with proteases under different conditions. The results showed that only two of the fifteen proteases assayed were able to efficiently degrade the protein at acidic pH, as determined by SDS-PAGE. These two commercial acid proteases, derived from *Aspergillus niger*, decreased by more than 95% the immunoreactivity of Pru p 3 by ELISA using specific rabbit IgG, giving peptides lower than 3.2 kDa as determined by MALDI-TOF mass spectrometry. The hydrolysates obtained showed a greater than 70% decrease in reactivity of IgE compared to untreated Pru p 3 using three pools of sera from peach allergic individuals. Furthermore, when hydrolysates were tested by the prick test, in more than 90% of peach-allergic patients the average size of the wheal significantly decreased by between 72% and 85%. The results suggest that the acid protease from *Aspergillus niger* could be used to obtain novel hypoallergenic products more tolerable for peach-sensitive individuals.

Received 4th July 2024,  
Accepted 30th October 2024

DOI: 10.1039/d4fo03052d

rsc.li/food-function

### 1. Introduction

Food allergies are estimated to affect up to 8% of children and infants and about 2–5% of the adult population and their prevalence has increased in the last two to three decades.<sup>1</sup> Specifically, fruits are considered to be among the primary elicitors of food allergies in humans. In a comprehensive review spanning the years 2009–2023, it has been estimated that the global prevalence of fruit allergies ranges between 0.029% and 8%. In addition, variation among regions of fruit allergies is influenced by dietary habits, local fruit varieties and patterns of sensitization.<sup>2</sup>

Allergy to fruits presents two clinical patterns: one results from a primary sensitization to labile pollen allergens, which usually induces local oropharyngeal reactions, and the other results from a primary sensitization with fruit allergens, which frequently induces systemic reactions.<sup>3</sup>

A wide variety of fruits have been reported to trigger allergic reactions that are listed in the database (<https://www.allergen.org>) of the World Health Organization and International Union of Immunological Societies (WHO/IUIS). In addition, some of the most prevalent and widely studied are reactions to fruits of the Rosaceae family, of which peach is a notable example.<sup>4</sup>

The nonspecific lipid transfer proteins (LTPs) from the Rosaceae fruits have been recognized as major allergens for allergies not related to pollen.<sup>5</sup> The proteins of the LTP family are considered to be true allergens because of their high resistance to digestive enzymes, as well as their ability to induce oral sensitization and produce severe and systemic symptoms, often life-threatening by producing anaphylactic reactions.<sup>6</sup>

Pru p 3 from peach belongs to the LTP family and. It has a molecular weight of 9 kDa and a basic isoelectric point. Its main structural motif is represented by a compact  $\alpha$ -helix domain where four helices are connected by short loops. The

<sup>a</sup>Departamento de Producción Animal y Ciencia de Los Alimentos. Facultad de Veterinaria. Instituto Agroalimentario de Aragón (IA2) (Universidad de Zaragoza-CITA), Spain. E-mail: dperez@unizar.es

<sup>b</sup>Servicio de Alergología, Hospital Clínico Universitario Lozano Blesa, Zaragoza, Spain

<sup>c</sup>Instituto de Investigación Sanitaria Aragón (IIS Aragón), Zaragoza, Spain

<sup>d</sup>Departamento de Medicina, Psiquiatría y Dermatología, Facultad de Medicina, Universidad de Zaragoza, Spain

† Electronic supplementary information (ESI) available. See DOI: <https://doi.org/10.1039/d4fo03052d>



protein contains eight cysteine residues that form four disulfide bridges, which confer it a high resistance to processing.<sup>5</sup> In addition, it has been shown that although technological treatments applied to Pru p 3 induce a certain degree of denaturation, the protein maintains its allergenic potential as determined by IgE-binding or by skin prick test in peach-allergic individuals. Thus, Pru p 3 shows a high resistance to heat treatments up to 100–120 °C (for 15 seconds to 2 hours) maintaining its allergenicity after heat processing.<sup>7–9</sup> Likewise, it has been shown that Pru p 3 subjected to other processing technologies like high pressure, pulsed electric fields or ultrasound maintains its allergenic potential.<sup>9–12</sup> These findings suggest that LTP proteins maintain their allergenic capacity in processed fruit products.

From our knowledge, there is very limited information about the effect of proteolytic enzymes on Pru p 3. Brenna *et al.* (2000)<sup>7</sup> studied the effect of acid proteases from *Rhizopus* spp. and *Aspergillus saitoi* on Pru p 3 and found that the protein band could be observed using SDS-PAGE after 60 min of reaction with both enzymes. Wijesinha-Bettoni *et al.* (2010)<sup>13</sup> performed a simulated gastrointestinal digestion of Pru p 3 using pepsin, trypsin and chymotrypsin. They observed that the protein is resistant to gastric digestion and that only two of the 14 potential tryptic and chymotryptic cleavage sites were cleaved in the simulated gastroduodenal digest. Thus, after initial cleavage by chymotrypsin between Tyr79 and Lys80, the resulting 7940 Da polypeptide is cleaved by trypsin between Arg39 and Thr40. In the study by Cavatorta *et al.*, (2010)<sup>14</sup> carried out using simulated gastrointestinal digestion on Pru p 3, the authors showed that about 35% of the protein remains still intact after extensive digestion. Furthermore, they identified using liquid chromatography/mass spectrometry (LC/MS) the generated peptides of low and high molecular weight and after their separation by LC, dot blotting analysis of the fractions showed that the intact protein and the high molecular weight peptides were recognized by the sera of peach-allergic patients, whereas the small peptides were not reactive.

The aim of this study was to evaluate the effect of a large number of proteases from different origins on the degradation and allergenicity of Pru p 3. The extent of degradation was determined by SDS-PAGE and by sandwich ELISA using specific rabbit antibodies to Pru p 3, and the size of peptides was determined by MALDI-TOF mass spectrometry (MALDI-TOF MS). Allergenicity was determined “*in vitro*” by a competitive enzyme linked fluorescent immunoassay (ELFIA) using three pools of sera from peach-allergic individuals, and “*in vivo*” using the skin prick test.

## 2. Materials and methods

### 2.1. Purification of Pru p 3

Peach (*Prunus persica*) extract was prepared from fresh peel from the Spanish indigenous variety “amarillo tardío”, clone calante. Peach peels were homogenised at a ratio of 1 : 2 (w : v)

with 10 mM sodium phosphate buffer (pH 5.6) containing 10 mM sodium diethyldithiocarbamate (DIECA), 2% solid polyvinylpyrrolidone (PVPP), 2 mM ethylenediamine tetraacetic acid (EDTA) and 3 mM sodium azide using an ultraturax. The mixture was kept under agitation for 2 h at 4 °C and centrifuged at 12 000g for 30 min at 4 °C. The supernatant was applied to a SP-Sepharose column (5 × 2 cm) and after washing with 10 mM sodium phosphate buffer, pH 5.6, the retained proteins were eluted using the same buffer containing 1 M NaCl. Fractions eluted were mixed and subjected to ultrafiltration using a membrane of 30 kDa. The permeate obtained, containing Pru p 3, was concentrated using a membrane of 3 kDa and subjected to SDS-PAGE. The degree of purity of Pru p 3, determined by densitometry of the stained gel, was higher than 95%.

### 2.2. Obtention and conjugation of anti-Pru p 3 antibodies

Purified Pru p 3 was inoculated in rabbits to obtain antisera as previously described.<sup>15</sup> All procedures carried out with animals were approved by the Ethics Committee for Animal Experiments at the University of Zaragoza (Project Licence PI 30/19) and are in compliance with the Spanish policy RD53/2013 for the correct use and care of animals, which meets the European Union’s requirements (EU Directive 2010/63).

Specific antibodies anti-Pru p 3 were isolated by affinity chromatography using a HiTrap NHS activated HP column (GE Healthcare, Fairfield, Connecticut, USA) coupled with Pru p 3 as previously described.<sup>12</sup> Then, purified antibodies were labelled with horseradish peroxidase (HRP) using the Lighting-link HRP conjugation kit (Innova Biosciences, Cambridge, UK).

### 2.3. Enzymatic treatment of Pru p 3

Pru p 3 protein (1 mg mL<sup>-1</sup>) and enzymes were prepared in McIlvaine buffer, containing 0.2 M disodium phosphate and 0.1 M citric acid, which were mixed to obtain pH values of 7.0, 6.0 and 3.3.<sup>16</sup> The enzymatic preparations used were protease from *Rhizopus* spp., protease from bovine pancreas, pronase from *Streptomyces griseus*, chymotrypsin from bovine pancreas, alcalase from *Bacillus licheniformis*, papain from papaya latex, bromelain from pineapple stem, ficin from fig tree latex, chymosin from calf stomach, pepsin from porcine gastric mucosa (Sigma-Aldrich, Poole, United Kingdom), animal rennet from ruminant stomach, vegetal rennet from *Rhizomucor miehei* and vegetal rennet from *Cynara cardunculus* (Laboratorios Arroyo, Cantabria, Spain). Commercial food grade NATUZYM® AP (NAP) and Acid Stable Protease (ASP), both derived from *Aspergillus niger*, were kindly supplied by WeissBioTech GmbH (Ascheberg, Germany) and by Bio-Cat (Troy, Va, EEUU), respectively.

The hydrolysis treatments were carried out under the conditions of pH and temperature indicated in Table 1, which included the optimal pH and temperature values of enzymes, among others. The enzymes were added at the ratio of 1 : 40 (w/v) except for NAP and ASP that were added at 3% (v/v) and 1% (w/v), following the manufacturer’s instructions. After incubation, the enzymes were inactivated by heating at 100 °C for



**Table 1** Proteases and conditions assayed to determine the degradation of Pru p 3

pH 7	37 °C	Bovine pancreas	Pronase
	50 °C	Chymotrypsin	Alcalase
pH 6	50 °C	Ficin	Bromelain
	65 °C	Papain	
pH 3.5	37 °C	Chymosin	Microbial rennet
		Pepsin	Animal rennet
	50 °C	Vegetable rennet	
		Acid stable protease (ASP) NATUZYM® AP (NAP)	<i>Rhizopus</i> spp.

5 min in a thermostatic bath. A control containing the protein without enzymes was maintained at the same temperature and pH for the duration of the hydrolysis reaction.

#### 2.4. SDS-PAGE

Hydrolysates obtained after treatment with proteases were analysed by SDS-PAGE under reducing conditions according to Laemmli (1970) using 4–20% precast polyacrylamide gels on a Mini PROTEAN Tetra Cell (Bio-Rad, Milan, Italy).<sup>17</sup> Gels were stained with Coomassie Brilliant Blue R-250.

#### 2.5. Sandwich ELISA

The concentration of immunoreactive Pru p 3 in untreated and treated samples was determined by a previously developed sandwich ELISA.<sup>12</sup> Briefly, wells of microtiter plates were coated with 120 µl of anti-Pru p 3 antibodies (1 µg ml<sup>-1</sup>) and incubated overnight at 4 °C. After washing, wells were blocked with 300 µl of ovalbumin at 3% (w/v) for 2 h. For the assay, wells were incubated with 100 µl per well of standards or samples diluted in 1.5 mM KH<sub>2</sub>PO<sub>4</sub>, 8 mM Na<sub>2</sub>HPO<sub>4</sub>, 0.14 mM KCl and 0.14 M NaCl buffer, pH 7.4 (PBS) containing 0.1% bovine serum albumin (BSA) and 5% sucrose for 1 h. After washing with PBS containing 0.05% Tween 20 (PBST), wells were incubated with 100 µl of an appropriate dilution of anti-Pru p 3 antibodies labelled with peroxidase. After washing again, 100 µl per well of a commercial peroxidase substrate containing tetramethylbenzidine (TMB) was added. After 30 min, the enzymatic reaction was stopped by adding 50 µl per well of 2 M H<sub>2</sub>SO<sub>4</sub> and the absorbance was read at 450 nm. All samples and standards were assayed in triplicate.

#### 2.6 Mass determination of proteins and peptides by MALDI-TOF MS

The hydrolysates obtained using ASP were analysed by MALDI-TOF MS in the Proteomic Service of the Instituto Aragonés de Ciencias de la Salud (Zaragoza, Spain). Samples were first treated with 0.1% trifluoroacetic acid (TFA). Then, they were mixed with the matrix (a saturated solution of sinapinic acid at a concentration of 10 mg mL<sup>-1</sup> prepared in 50% acetonitrile containing 0.1% trifluoroacetic acid) and deposited in duplicate on a MALDI-Opti-ToF plate 384 (Sciex, Framingham, MA, EEUU).

The analysis was performed in positive linear mode with an accelerating voltage of 20 kV, a mass range of 1000–20 000 Da,

focus 9000, 1000 shots per spectrum and a laser intensity of 4800. The equipment was calibrated with a mixture of protein standards (Proteo Mass Protein MALDI-MS Calibration Kit MSCAL3, Sigma).

#### 2.7. Patients and skin prick test

A number of 21 adult patients allergic to peach were voluntarily recruited at the Allergy Department of the Hospital Clínico Universitario Lozano Blesa of Zaragoza (Spain). Patients who met the criteria for inclusion had a clinical diagnosis of LTP allergy, characterized by experiencing symptoms upon consuming peach and exhibiting a positive prick test reaction to peach LTP (ALK-Abelló S.A., Madrid, Spain) or possessing specific IgE levels to Pru p 3 greater than 0.35 kU L<sup>-1</sup> detected using the ImmunoCAP FEIA system (ThermoFisher Scientific/Phadia, Uppsala, Sweden). All patients were previously given a questionnaire and signed an informed consent for using the results of this study. The study protocol was approved by the clinical research ethics committee of Aragón (CEICA) (projects PI15/0323 and PI17/0351) in accordance with the principles contained in the Declaration of Helsinki and within the framework of current legal regulations for biomedical research studies with biological samples (Law 14/2007 on Biomedical Research, Directive 2004/23/EC of March 31 and RD 411/1996). All samples were tested in a unique session for each patient.

The skin prick test was performed according to the EAACI recommendations<sup>18</sup> with samples of purified Pru p 3 untreated and subjected to enzymatic treatment and with commercial peach LTP (ALK-Abelló S.A., Madrid, Spain) commonly used for LTP allergy detection. Negative and positive controls of saline solution and histamine hydrochloride (10 mg mL<sup>-1</sup>), respectively, were also tested in each patient. The major and minor diameters of the wheal were measured and their product was calculated. A positive result is considered when one of the diameters is greater than 3 mm or greater than that produced by the positive control. The percentage of increase or decrease in the product of the diameters of hydrolysed samples with respect to the untreated protein was estimated for each patient. After performing the prick test in each patient, a blood sample was extracted and serum, obtained after clotting and centrifugation, was stored at -20 °C until used.

In addition, patients were distributed into three groups based on their symptoms: at least one of four symptoms (urticaria, angioedema, asthma, and abdominal pain) in an acute outbreak (ALOS), an oral allergy syndrome (OAS), or severe symptoms such as anaphylactic shock (ANS).

#### 2.8. Competitive and non-competitive inhibition enzyme linked fluorescent immunoassay (ELFIA)

The presence of specific IgE (sIgE) against Pru p 3 was determined in all individual sera and in the three pools of sera from patients allergic to peach using Pru p 3 ImmunoCAP (reference f420, ImmunoCAP FEIA system, ThermoFisher Scientific/Phadia, Uppsala, Sweden) in a Phadia 100 system.



Assays were performed using a non-competitive format following the manufacturer's instructions for sIgE determination.

To compare the binding of sIgE to untreated and enzymatic treated Pru p 3 samples, a competitive assay was carried out using Pru p 3 ImmunoCAP. To this end, untreated and treated Pru p 3 samples (1/40 in PBS) were mixed with the pool of sera (1 : 1, v/v in PBS) and sIgE was determined as described by Tobajas *et al.*, (2020).<sup>12</sup>

Changes in IgE-binding to Pru p 3 induced by enzymatic treatments (sIgE sample) with respect to an untreated sample (sIgE 100%) and negative control (buffer, sIgE 0%) were estimated as follows:

$$\text{IgE binding (\%)} = \frac{\text{sIgE sample} - \text{sIgE 0\%}}{\text{sIgE 100\%} - \text{sIgE 0\%}} \times 100$$

## 2.9. Statistical analysis

Data from the prick test were statistically analysed using the SPSS version 15.0 for Windows (Statistical Package for the Social Sciences (SPSS) Inc., Chicago, IL, USA). To summarize the data, descriptive statistics, frequencies, and percentages, as well as graphs and charts, were used. The data were found to have a non-normal distribution using the Kolmogorov–Smirnov and Shapiro–Wilk *W* tests, and therefore non-parametric tests were used for the analysis. The Wilcoxon signed-rank test was used to determine differences between control and treated samples. A significance level of  $p < 0.05$  was pre-defined in all cases.

For Pru p 3 concentration determined after enzymatic treatment by ELISA, data were analysed for statistical significance with GraphPad Prism 8 software, using a one-way analysis of variance (ANOVA) with Tukey's multiple comparison test.

## 3. Results and discussion

### 3.1 Effect of proteolysis on the degradation of Pru p 3

The effect of treatment with different proteases on the degradation of Pru p 3 was determined using SDS-PAGE. In the case of those enzymes in which a considerable decrease in the intensity of the Pru p 3 band was observed when incubating under acidic pH conditions, which correspond to those of fruit extracts, the hydrolysates were further analysed. These analyses included the determination of the loss of reactivity with rabbit antibodies specific to Pru p 3 using a sandwich ELISA previously developed,<sup>12</sup> and the characterization of hydrolysates by MALDI-TOF MS.

The effect of treatment of purified Pru p 3 with different proteases on the degradation of the protein by SDS-PAGE is shown in Fig. 1. These treatments were performed at the optimum pH, temperature and enzyme–substrate ratio of the corresponding enzymes and some additional conditions were also assayed for proteases from *A. niger*. Untreated protein showed a major band of 9 kDa which corresponds to the molecular weight of Pru p 3.<sup>5</sup> As can be observed, Pru p 3 was not affected by papain, bromelain, ficin, alcalase, chymosin,

and animal, microbial and vegetable rennets, as no decrease in the intensity of the Pru p 3 band was observed. For pronase and chymotrypsin, a decrease in the intensity of the Pru p 3 band was observed besides the appearance of a band of lower molecular weight indicating a considerable degradation of Pru p 3. When assaying NAP and ASP, both derived from *Aspergillus niger*, a marked disappearance of the Pru p 3 band occurred and it could not be visualized after incubation with protease from bovine pancreas. Therefore, it was assumed that peptides with low molecular weight were produced by these enzymes that could have escaped from the gel.

Other bands of high molecular weight present only in hydrolyzed samples correspond to either proteases or other proteins present in enzymatic preparations as some of them are extracts of animal or vegetal origin and others are produced by fermentation of different fungi.


As the pH of peach is about 3.5, the proteases to be used during juice processing to degrade Pru p 3 should be effective under those acidic conditions. Therefore, some additional experiments were performed using protease from bovine pancreas, whose optimum pH and temperature are 7.5 and 37 °C, to determine if it could maintain its enzymatic activity at lower pH values. The results showed that its activity decreased markedly with a decrease in pH to 6.0 and 5.0, with very long times (72 h) needed at 25 °C to achieve a considerable degradation (see the ESI, Fig. S1†). These results indicate that protease from bovine pancreas is not suitable for application in the processing of peach derivatives, as the required pH conditions of the enzyme would induce undesirable browning of the product, since the optimal pH for the action of polyphenol oxidase browning enzyme is 5.0–7.0, and it shows inhibition under acidic conditions.<sup>19</sup>

NAP and ASP were also assayed maintaining their optimum pH (3.5) but under different conditions of temperature and time (25 °C and 24 h), instead of 50 °C for 2 h, as recommended by the manufacturers. The results showed a similar degradation of Pru p 3 under both conditions (Fig. 1). These findings indicate that the proteolysis treatment could be performed by adding the protease preparations sterilized by microfiltration after juice processing to carry out hydrolysis during storage before going on the market.

Until now, few studies have been performed to determine the effect of enzymatic treatment on Pru p 3. Brenna *et al.* (2000)<sup>7</sup> using SDS-PAGE determined the action of acidic proteases from *Aspergillus saitoi* and *Rhizopus* spp. at pH 3.4 and 50 °C on a semi-purified extract of Pru p 3 and found that the protein band was present after 60 minutes of reaction time, suggesting that both enzymes were not able to hydrolyze the protein.

Based on the results obtained in our study, the most efficient enzymes to degrade Pru p 3 were NAP and ASP and therefore they were used in additional experiments. Furthermore, acid protease from *Rhizopus*, which was shown to be ineffective to degrade Pru p 3, was used as a comparison.





**Fig. 1** SDS-PAGE on polyacrylamide gel (4–20%) under reducing conditions of untreated and protease-treated Pru p 3. The pH, temperature (°C) and time (h) of the treatment are indicated in parentheses. Molecular weight marker (MW). Control untreated Pru p 3 (C). Lane 1, pronase (7/37/2). Lane 2, chymotrypsin (7/50/2). Lane 3, bovine pancreas (7/37/2). Lane 4, papain (6/65/2). Lane 5, bromelain (6/50/2). Lane 6, ficin (6/50/2). Lane 7, alcalase (7/50/2). Lane 8, NATUZYM® AP (NAP) (3.5/50/2). Lane 9, NAP (3.5/25/24). Lane 10, Acid Stable Protease (ASP) (3.5/50/2). Lane 11, ASP (3.5/25/24). Lane 12, *Rhizopus* (3.5/50/2). Lane 13, pepsin (3.5/37/2). Lane 14, chymosin (3.5/37/2). Lane 15, microbial rennet (3.5/37/2). Lane 16, animal rennet (3.5/37/2). Lane 17, vegetable rennet (3.5/37/2).

The effect of NAP and ASP on the concentration of immunoreactive Pru p 3, determined using a previously developed specific sandwich ELISA,<sup>12</sup> is shown in Fig. 2. Assays performed with both proteases incubated with the purified protein at pH 3.5 under both of the tested conditions (50 °C, 2 h and 25 °C, 24 h) indicated that the concentration of immunoreactive Pru p 3 decreased markedly, by more than 90% compared to the untreated protein, whereas treatment


with protease from *Rhizopus* showed an increase of immunoreactive Pru p 3 of about 20%, although the differences were non-significant. Similar results were obtained when the incubation with NAP or ASP at 25 °C for 24 h was performed with peach extract or commercial peach juice, obtaining a decrease in IgG reactivity of more than 93% (results not shown). These findings support the treatment with NAP and ASP inducing a marked loss of epitopes recognized by IgG, which suggests intensive degradation of the protein.

The analysis of hydrolysates obtained with ASP by MALDI-TOF MS is shown in Fig. S2(a–e).† Untreated Pru p 3 exhibits two peaks of molecular weights of 9134 Da and 4751 Da which correspond to the native Pru p 3 and to the molecular ion of the protein ionized with a +2 charge, respectively (see the ESI, Fig. S2†).

In the hydrolysates generated with ASP, the 9 kDa peak belonging to Pru p 3 was not observed and the predominant peptides obtained had molecular weights of less than 3.2 kDa and 1.8 kDa for treatments at 50 °C for 2 h and 25 °C for 24 h, respectively (Fig. S2(b and c)†). It should be noted that although the optimum treatment temperature of ASP is 50 °C, treatment at 25 °C for 24 h was even more effective as it produced peptides of lower molecular weight. However, the sample incubated with protease from *Rhizopus* (Fig. S2d†) displays a similar chromatographic profile to that obtained with the native protein, indicating that it is not able to degrade Pru p 3.

The analysis of the ASP in buffer by MALDI-TOF MS gave peaks within the molecular weight range from 20 to 100 kDa, as observed in the electrophoretic profile (Fig. S2e†).

These findings suggest that Pru p 3 degradation could be performed either by adding the protease during the juice clarification process with pectinolytic enzymes to decrease the vis-



**Fig. 2** Degradation of Pru p 3 determined by sandwich ELISA treatment with NATUZYM® AP (NAP), Acid Stable Protease (ASP) and protease from *Rhizopus* (PR) at pH 3.5. Results are the mean  $\pm$  standard deviation of data from two experiments analysed in triplicate and are expressed as percentage of control untreated protein (100%). Numbers correspond to the temperature (°C) and time (h) of treatment. Asterisks indicate significant differences compared with the control: \* $p < 0.05$ ; \*\* $p < 0.01$ ; \*\*\* $p < 0.001$ ; \*\*\*\* $p < 0.0001$ .



cosity,<sup>20</sup> which is performed at 50 °C for 2 hours before pasteurization, or by sterilization by filtration into the product packaging after heat treatment so that the enzyme can act during the storage period before going on the market.

This approach to hydrolyze a food component which causes adverse effects in sensitized individuals is already a standard practice in lactose-free milk for lactose-intolerant individuals. In these cases, lactase is usually aseptically added to the finished product to hydrolyze lactose during the period during which the product remains in the factory for quality control checking before being released to the market.<sup>21</sup>


According to the European Society for Paediatric Gastroenterology, Hepatology and Nutrition (ESPHGAN) all peptides in hydrolysed formula milk for children allergic to milk proteins should have a size lower than 3 kDa and be dominated by peptides with a size of about 1.5 kDa, hence containing at the maximum one linear epitope. Thus they should not be able to cross-link IgEs on the surface of tissue mast cells and blood basophils and cause allergic reactions.<sup>22</sup> Therefore, the peptides obtained in the degradation of Pru p 3 using NAP and ASP would be within the molecular weight range indicated by ESPHGAN to consider a food product as hypoallergenic.

### 3.2 Effect of proteolysis on allergenicity of Pru p 3

The effect of proteolysis on the allergenicity of Pru p 3 was studied using NAP and ASP, as they showed the most efficient degradation of the protein under acidic conditions. The impact of proteolysis on the allergenicity of Pru p 3 was determined by “*in vitro*” and “*in vivo*” techniques.

The “*in vitro*” technique consists of a competitive ELFIA technique as previously described by Tobajas *et al.* (2020).<sup>12</sup> All sera were previously tested using a non-competitive ELFIA format. Three pools of sera from peach-allergic patients who presented symptoms of different severities (oral allergy syndrome, at least one systemic symptom or anaphylactic shock) were assayed. To this end, serum from allergic individuals presenting an IgE level against Pru p 3 higher than 1.30 kU L<sup>-1</sup> was mixed to prepare the pools. The specific IgE levels in these three pools were 5.43, 6.84, and 9.86 kU L<sup>-1</sup>, respectively.

The results obtained (Fig. 3) showed that hydrolysates of Pru p 3 obtained with NAP and ASP incubated at 50 °C for 2 hours or at 25 °C for 24 hours induced a reduction in reactivity of the protein with IgE, which ranged between 75% and 88% for the OAS pool, between 77% and 84% for the ALOS pool and between 50% to 68% for the AS pool, compared to the untreated sample (100%). Likewise, experiments performed with hydrolysates obtained from a peach extract or a commercial peach juice incubated with ASP at 25 °C for 24 h using the AS pool showed a decrease in IgE reactivity greater than 80% with respect to untreated samples (100%). The higher loss of reactivity obtained when using these hydrolysates compared to those obtained with the purified protein could possibly be due to the expected lower concentration of Pru p 3 present in the extract and juice (results not shown). In contrast, the reactivity of Pru p 3 incubated with the protease from *Rhizopus* towards the three pools of sera was similar to



**Fig. 3** Effect of treatment with NATUZYM® AP (NAP), Acid Stable Protease (ASP) and protease from *Rhizopus* (PR) on the allergenicity of Pru p 3 determined by indirect competitive immunofluorescence assay (ELFIA). The three pools of sera assayed correspond to patients who showed one of these three types of symptoms: OAS, oral allergy syndrome; ALOS, at least one of four symptoms (urticaria, angioedema, asthma, abdominal pain) in an acute outbreak; ANS, anaphylactic shock. Numbers correspond to the temperature (°C) and time (h) of the treatment. The results are expressed as percentage of the untreated sample (100%).

that of the untreated protein. These results suggest that treatment with proteases from *Aspergillus niger* markedly decreases the allergenic potential of Pru p 3 whereas the protein maintains allergenicity after treatment with protease from *Rhizopus*.

It is noticeable that the decrease of reactivity of Pru p 3 with IgG obtained in this study is higher than that obtained with IgE, as this fact could be due to a comparatively higher loss of protein epitopes recognized by IgG.

In the study of simulated gastrointestinal digestion of purified Pru p 3 performed by Cavatorta *et al.* (2010),<sup>14</sup> the authors observed that the dot-blot analysis using sera of allergic patients showed that the intact protein and the high molecular weight peptides obtained after treatment were recognized by IgE, whereas the small peptides were not reactive. These findings indicate that Pru p 3 retains its ability to bind IgE after gastroduodenal digestion and hence its allergenic potential.

On the other hand, skin prick tests were carried out in individuals allergic to LTP from peach to determine the effect of enzymatic treatment on “*in vivo*” allergenicity. The samples tested included untreated Pru p 3 and hydrolysates obtained with NAP or ASP incubated at 50 °C for 2 h and at 25 °C for 24 h or acid protease from *Rhizopus* incubated at 50 °C for 2 h.

Table 2 shows the level of specific IgE to Pru p 3 in each patient's serum, the symptoms indicated by patients and the product of the major and minor diameters of the wheals corresponding to untreated and enzymatic treated protein for each allergic individual. Results expressed as the products of diameters were preferred as some individuals presented an irregular area or a pseudopod in the prick test.<sup>23</sup> The percentage cutaneous response related to the corresponding untreated protein (100%) is also given.



**Table 2** Effect of treatment of Pru p 3 with NATUZYM® AP (NAP), Acid Stable Protease (ASP) and protease from *Rhizopus* (PR) on the allergenicity of Pru p 3 determined by the prick test in peach-allergic patients. The results correspond to the product of the wheal diameters. Treatments were performed at 50 °C for 2 h or at 25 °C for 24 h. Changes in allergenicity are also expressed as the percentage of the wheal diameter product with respect to the untreated sample (100%). C, untreated control sample

Patient	S	kU L <sup>-1</sup>	C	Wheal diameter product					Allergenicity (%)				
				ASP 50/2	ASP 25/24	NAP 50/2	NAP 25/24	PR 50/2	ASP 50/2	ASP 25/24	NAP 50/2	NAP 25/24	PR 50/2
LTP01	ALOS	1.09	80	8	12	0	12	112	10	15	0	15	140
LTP02	ALOS	0.03	36	16	16	9	9	70	44	44	25	25	194
LTP03	ALOS	15.1	80	16	9	16	0	98	20	11	20	0	123
LTP04	ALOS	2.56	80	16	16	9	9	140	20	20	11	11	175
LTP05	ALOS	0.35	168	42	36	25	56	320	25	21	15	33	190
LTP06	OAS	9.98	260	16	12	16	20	84	6	5	6	8	32
LTP07	ANS	1.57	240	35	25	25	16	126	15	10	10	7	53
LTP08	OAS	2.59	112	56	20	20	20	56	50	18	18	18	50
LTP09	ANS	0.92	63	30	8	8	12	72	48	13	13	19	114
LTP10	ANS	2.03	180	36	16	16	25	90	20	9	9	14	50
LTP11	OAS	6.83	930	200	144	140	98	480	22	15	15	11	52
LTP12	ANS	0.75	168	128	60	98	35	390	76	36	58	21	232
LTP13	ALOS	0.12	63	12	0	0	0	72	19	0	0	0	114
LTP14	ALOS	0.6	144	0	0	16	20	56	0	0	11	14	39
LTP15	OAS	4.22	180	0	0	25	0	160	0	0	14	0	89
LTP16	ALOS	6.21	56	36	20	16	0	325	64	36	29	0	580
LTP17	ALOS	9.01	30	0	0	0	0	12	0	0	0	0	40
LTP18	ANS	4.99	36	35	30	16	12	120	97	83	44	33	333
LTP19	ALOS	1.34	192	0	0	0	0	112	0	0	0	0	58
LTP20	ANS	13.8	192	25	20	16	0	120	13	10	8	0	63
LTP21	ANS	18.6	126	35	0	64	56	160	28	0	51	44	127

Symptoms (S) correspond to an oral allergy syndrome (OAS), at least one of these four symptoms (urticaria, angioedema, asthma, abdominal pain) in an acute outbreak (ALOS) or anaphylactic shock (ANS); kU L<sup>-1</sup> corresponds to sIgE of each patient determined by immunoCap.

It should be noted that the relationship between the products of the diameters of the wheals and the specific IgE values gave a very low correlation coefficient ( $r^2 = 0.0087$ ). Besides, it seems that there is no relationship between the severity of the symptoms and the product of the wheal or the level of specific IgE, which indicates that the allergenicity of Pru p 3 should be evaluated on an individual basis.

The comparison of the mean ranges of the product of wheal diameter between untreated and treated Pru p 3 with NAP and ASP showed significant differences under all assayed conditions ( $Z = -4.015$ ,  $p < 0.0001$ ). However, no significant differences were found for samples treated with protease from *Rhizopus* ( $Z = -0.313$ ,  $p = 0.754$ ).

Besides, when comparing Pru p 3 treated with NAP and ASP with the untreated protein, a marked decrease in reaction (wheal diameter product between 15% and 28% compared to control untreated protein) was obtained in 95–100% of patients (Table 3). Furthermore, no increase in the reaction was observed in any patient and no changes were seen in only one patient for the treatment with ASP at 50 °C during 2 h. However, when Pru p 3 was treated with protease from *Rhizopus*, 47.5% of patients showed a decrease of the wheal diameter product, with a mean value of 53.9%, whereas 47.5% of patients showed an increase, with an average value of 222%, and only 5% showed no changes.

The results of this study obtained after the treatment of Pru p 3 with proteases from *Aspergillus niger* (ASP and NAP) are very promising, as they indicate a notable decrease in the allergenic potential of the protein. Additionally, the impact of enzy-

**Table 3** Number of peach-allergic patients ( $n$ ) who showed an increase, no change or a decrease of allergenicity when Pru p 3 was assayed by the skin prick test. X (%) corresponds to the average value of the percentages of the product of diameters for each group. Pru p 3 was treated with NATUZYM® AP (NAP), Acid Stable Protease (ASP) and protease from *Rhizopus* (PR) at pH 3.5. The temperature (°C) and time (h) of the treatment are indicated in parentheses

Pru p 3 + protease	Group 1		Group 2		Group 3
	Decrease allergenicity		Increase allergenicity		No changes
	X (%)	$n$		$n$	$n$
ASP (50/2)	28.4	20	—	0	1
ASP (25/24)	15.1	21	—	0	0
NAP (50/2)	14.9	21	—	0	0
NAP (25/24)	15.2	21	—	0	0
PR (50/2)	53.9	10	199	10	1

matic treatment with proteases from *Aspergillus niger* on the allergenicity of Pru p 3 should also be studied using cellular techniques such as the basophil activation test,<sup>24</sup> “*in vivo*” animal models<sup>25</sup> and/or challenge tests in sensitized individuals, performed under medical supervision. These studies would allow to know whether hydrolysed products are devoid of risk and whether they would be effective in improving tolerance in allergic patients.<sup>26,27</sup>

Furthermore, a sensorial analysis of peach products obtained by enzymatic treatment should also be carried out to determine consumer acceptance, although it is expected that



the flavour would not be substantially modified due to the low protein content present in fruit-derived products.

To our knowledge, only two enzyme-modified products are available in the market for individuals sensitized to food proteins: hypoallergenic infant formulas for babies allergic to cow's milk proteins and gluten-free beer for individuals with celiac disease. The processing technology applied to manufacturing these products is based on the use of enzymes that efficiently hydrolyse proteins present in those foods.<sup>28,29</sup> These products can be ingested without causing any adverse symptoms in most sensitive individuals. Therefore, the products developed using the enzymatic treatment applied in our study would be the first hypoallergenic fruit-based products on the current market.

## 4. Conclusions

In this study, we have shown that enzymatic treatment with acid protease derived from *Aspergillus niger* induces a severe degradation of Pru p 3 producing peptides of molecular weight lower than 3 kDa. Furthermore, hydrolysis treatment is able to decrease the IgE binding of Pru p 3 "in vitro" and to markedly decrease the wheal reaction "in vivo" obtained by the prick test. Therefore, processing with acid proteases from *Aspergillus niger* could be used as a procedure to obtain fruit products with decreased allergenicity. It would also be necessary to carry out studies with acid protease from *Aspergillus niger* on a pilot scale to verify if the results obtained with purified Pru p 3 are reproducible in peach products under industrial conditions. Furthermore, studies should be performed in order to determine if proteins of the LTP family from other fruits are also effectively degraded by the acid protease applied in this study.

## Author contributions

A. P. T.: writing – original draft, writing – review & editing, methodology, investigation, data curation, and conceptualization. A. A.-G.: writing – review & editing, investigation, and data curation. J. L. C.: writing – review & editing, formal analysis, and investigation. C. C.: writing – review & editing, conceptualization, methodology, resources, and funding acquisition. A. C.: writing – review & editing, investigation. C. E.: writing – review & editing, and investigation. L. S.: writing – review & editing, and methodology. M. D. P.: writing – review & editing, conceptualization, methodology, resources, funding acquisition, project administration, and supervision.

## Ethical approval

The study protocol with humans was approved by the Clinical Research Ethics Committee of Aragón (CEICA) (Projects PI15/0323 and PI17/0351). The study protocol with animals was

approved by the Ethics Committee for Animal Experiments from the University of Zaragoza (Project PI 30/19).

## Data availability

The authors confirm that the data supporting the findings of this study are available within the article. Additional data that support the findings of this study are available from the corresponding author, MDP, upon reasonable request.

## Conflicts of interest

There are no conflicts to declare.

## Acknowledgements

The authors would like to acknowledge the use of the Proteomics Facility of Instituto Aragonés de Ciencias de la Salud (IACS) and of the Servicio General de Apoyo a la Investigación-SAI, Universidad de Zaragoza. We thank Esther Carbajo and Sofía Victoria Lozano for carrying out the skin prick tests and blood extractions. This work has been supported by Fundación de la Sociedad Española de Alergología e Inmunología Clínica (SEAIC) (Ref. BECA 20A8) and by Gobierno de Aragón (Ref. A20\_23R) and the European Social Fund (ESF). Ana Pilar Tobajas, Alba Civera and Clara Esteban are grateful to the Gobierno de Aragón for a predoctoral contract.

## References

- 1 S. H. Sicherer and H. A. Sampson, Food allergy: A review and update on epidemiology, pathogenesis, diagnosis, prevention, and management, *J. Allergy Clin. Immunol.*, 2018, **141**, 41–58.
- 2 T. Krikeerati, P. Rodsaward, J. Nawiboonwong, K. Pinyopornpanish, S. Phusawang and M. Sompornrattanaphan, Revisiting fruit allergy: Prevalence across the globe, diagnosis, and current management, *Foods*, 2023, **12**, 4083.
- 3 A. K. G. Hassan and Y. P. Venkatesh, An overview of fruit allergy and the causative allergens, *Eur. Ann. Allergy Clin. Immunol.*, 2015, **47**, 180–187.
- 4 J. Wang, S. K. Vanga and V. Raghavan, Effect of pre-harvest and post-harvest conditions on the fruit allergenicity: A review, *Crit. Rev. Food Sci. Nutr.*, 2019, **59**, 1027–1043.
- 5 M. Sinha, R. P. Singh, G. S. Kushwaha, N. Iqbal, A. Singh, S. Kaushik, P. Kaur, S. Sharma and T. P. Singh, Current overview of allergens of plant pathogenesis related protein families, *Sci. World J.*, 2014, **2014**, 1–19.
- 6 S. K. Vanga, M. Jain and V. Raghavan, Significance of fruit and vegetable allergens: Possibilities of its reduction through processing, *Food Rev. Int.*, 2018, **34**, 103–125.



- 7 O. Brenna, C. Pompei, C. Ortolani, V. Pravettoni, E. A. Pastorello and L. Farioli, Technological processes to decrease the allergenicity of peach juice and nectar, *J. Agric. Food Chem.*, 2000, **48**, 493–497.
- 8 A. I. Sancho, N. M. Rigby, L. Zuidmeer, R. Asero, G. Mistrello, S. Amato, E. Gonzalez-Mancebo, M. Fernandez-Rivas, R. Ree and E. N. C. Mills, The effect of thermal processing on the IgE reactivity of the non-specific lipid transfer protein from apple, Mal d 3, *Allergy*, 2005, **60**, 1262–1268.
- 9 A. P. Tobajas, A. Agulló-García, J. L. Cubero, C. Colás, A. Civera, S. Condón, L. Sánchez and M. D. Pérez, Effect of thermal and ultrasound treatments on denaturation and allergenic potential of Pru p 3 protein from peach, *Eur. Food Res. Technol.*, 2022, **249**, 485–495.
- 10 C. Garino, F. Zitelli, F. Travaglia, J. D. Coïsson, G. Cravotto and M. Arlorio, Evaluation of the impact of sequential microwave/ultrasound processing on the IgE binding properties of Pru p 3 in treated peach juice, *J. Agric. Food Chem.*, 2012, **60**, 8755–8762.
- 11 M. Lavilla, J. Orcajo, A. Díaz-Perales and P. Gamboa, Examining the effect of high pressure processing on the allergenic potential of the major allergen in peach (Pru p 3), *Innovative Food Sci. Emerging Technol.*, 2016, **38**, 334–341.
- 12 A. P. Tobajas, A. Agulló-García, J. L. Cubero, C. Colás, I. Segura-Gil, L. Sánchez, M. Calvo and M. D. Pérez, Effect of high pressure and pulsed electric field on denaturation and allergenicity of Pru p 3 protein from peach, *Food Chem.*, 2020, **321**, 126745.
- 13 R. Wijesinha-Bettoni, Y. Alexeev, P. Johnson, J. Marsh, A. I. Sancho, S. U. Abdullah, A. R. Mackie, P. R. Shewry, L. J. Smith and E. N. C. Mills, The structural characteristics of nonspecific lipid transfer proteins explain their resistance to gastroduodenal proteolysis, *Biochemistry*, 2010, **49**, 2130–2139.
- 14 V. Cavatorta, S. Sforza, G. Aquino, G. Galaverna, A. Dossena, E. A. Pastorello and R. Marchelli, In vitro gastrointestinal digestion of the major peach allergen Pru p 3, a lipid transfer protein: Molecular characterization of the products and assessment of their IgE binding abilities, *Mol. Nutr. Food Res.*, 2010, **54**, 1452–1457.
- 15 Z. Wehbi, M.-D. Pérez, L. Sánchez, C. Pocoví, C. Barbana and M. Calvo, Effect of heat treatment on denaturation of bovine  $\alpha$ -lactalbumin: Determination of kinetic and thermodynamic parameters, *J. Agric. Food Chem.*, 2005, **53**, 9730–9736.
- 16 T. C. McIlvaine, A buffer solution for colorimetric comparison, *J. Biol. Chem.*, 1921, **49**, 183–186.
- 17 U. K. Laemmli, Cleavage of structural proteins during the assembly of the head of bacteriophage T4, *Nature*, 1970, **227**, 680–685.
- 18 S. G. Johansson, J. O. Hourihane, J. Bousquet, C. Bruijnzeel-Koomen, S. Dreborg, T. Haahtela, M. L. Kowalski, N. Mygind, J. Ring, P. van Cauwenberge, M. van Hage-Hamsten, B. Wüthrich and EAACI (the European Academy of Allergology and Clinical Immunology) nomenclature task force, A revised nomenclature for allergy. An EAACI position statement from the EAACI Nomenclature Task Force, *Allergy*, 2001, **56**, 813–824.
- 19 B. Singh, K. Suri, K. Shevkani, A. Kaur, A. Kaur and N. Singh, Enzymatic browning of fruit and vegetables: A review, in *Enzymes in Food Technology*, ed. M. Kuddus, Springer Singapore, Singapore, 2018, pp. 63–78.
- 20 D. M. Barrett, L. Somogyi and H. S. Ramaswamy, *Processing Fruits: Science and Technology*, Editorial CRC Press, Boca Raton, FL, Second edn, 2004.
- 21 M. Harju, H. Kallioinen and O. Tossavainen, Lactose hydrolysis and other conversions in dairy products: Technological aspects, *Int. Dairy J.*, 2012, **22**, 104–109.
- 22 N. Z. Maryniak, A. I. Sancho, E. B. Hansen and K. L. Bøgh, Alternatives to cow's milk-based infant formulas in the prevention and management of cow's milk allergy, *Foods*, 2022, **11**, 926.
- 23 I. Vohlonen, E. O. Terho, A. Koivikko, T. Vanto, A. Holmén and O. P. Heinonen, Reproducibility of the skin prick test, *Allergy*, 1989, **44**, 525–531.
- 24 J. A. Cañas, N. Pérez-Sánchez, L. Lopera-Doblas, F. Palomares, A. Molina, J. Bartra, M. J. Torres, F. Gómez and C. Mayorga, Basophil activation test utility as a diagnostic tool in LTP allergy, *Int. J. Mol. Sci.*, 2022, **23**, 4979.
- 25 S. Benedé, D. Lozano-Ojalvo, R. López-Fandiño and E. Molina, A mouse model of oral sensitization to hen's egg white, in *Animal Models of Allergic Disease*, ed. K. Nagamoto-Combs, Springer US, New York, NY, 2021, vol. 2223, pp. 49–65.
- 26 S. Nagendran, N. Patel and P. J. Turner, Oral immunotherapy for food allergy in children: Is it worth it?, *Expert Rev. Clin. Immunol.*, 2022, **18**, 363–376.
- 27 C. Pereira, B. Bartolomé, J. A. Asturias, I. Ibarrola, B. Tavares, G. Loureiro, D. Machado and C. Chieira, Specific sublingual immunotherapy with peach LTP (Pru p 3). One year treatment: A case report, *Cases J.*, 2009, **2**, 6553.
- 28 K. L. Bøgh and J. M. Larsen, Agents of Change, in *Reducing Allergenicity by Proteolysis*, ed. A. L. Kelly and L. B. Larsen, Springer International, Cham, 2021, pp. 499–523.
- 29 N. Cela, N. Condelli, M. C. Caruso, G. Perretti, M. Di Cairano, R. Tolve and F. Galgano, Gluten-free brewing: Issues and perspectives, *Fermentation*, 2020, **6**, 53.

